Linezolid pharmacokinetics in an obese patient [4]

American Journal of Health-System Pharmacy

Volumn 62, Issue 5, 2005, Pages

  Mersfelder, Tracey L ^a   Smith, Curtis L ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b FERRIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; LINEZOLID; VANCOMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; BODY MASS; BODY WEIGHT; CASE REPORT; CELLULITIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; DRUG SOLUBILITY; HUMAN; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; OBESITY; PRIORITY JOURNAL;

EID: 14744306719     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.5.464a     Document Type: Letter

References (7)

1. Pharmacia, Inc. Zyvox (linezolid) package insert. Kalamazoo, MI; 2003 Nov.
2. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001; 358:1975-82.
3. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003; 124:1789-97.
4. Li JZ, Willke RJ, Pinto LA et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy. 2001; 21:263-74.
5. Gee T, Ellis R, Marshall G et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001; 45:1843-6.
6. Bauer LA. Applied clinical pharmacokinetics. New York: McGraw-Hill; 2001.
7. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis. 1997; 25:112-8.